-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Chemours, Raises Price Target to $23

Benzinga·02/23/2026 20:47:07
Listen to the news
UBS analyst Joshua Spector maintains Chemours (NYSE:CC) with a Buy and raises the price target from $18 to $23.